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Gradients of chemokines and growth factors guide migrating cells and morphogenetic
processes. Migration of antigen-presenting dendritic cells from the interstitium into the
lymphatic system is dependent on chemokine CCL21, which is secreted by endothelial
cells of the lymphatic capillary, binds heparan sulfates and forms gradients decaying into
the interstitium. Despite the importance of CCL21 gradients, and chemokine gradients in
general, the mechanisms of gradient formation are unclear. Studies on fibroblast growth
factors have shown that limited diffusion is crucial for gradient formation. Here, we used
the mouse dermis as a model tissue to address the necessity of CCL21 anchoring to
lymphatic capillary heparan sulfates in the formation of interstitial CCL21 gradients.
Surprisingly, the absence of lymphatic endothelial heparan sulfates resulted only in a
modest decrease of CCL21 levels at the lymphatic capillaries and did neither affect
interstitial CCL21 gradient shape nor dendritic cell migration toward lymphatic capillaries.
Thus, heparan sulfates at the level of the lymphatic endothelium are dispensable for the
formation of a functional CCL21 gradient.
Keywords: chemokine gradient, chemokine CCL21, chemotaxis, lymphatic system, lymphatic endothelium,
dendritic cell, heparan sulfateINTRODUCTION
Chemokines and growth factors form extracellular gradients, which guide migrating cells and
morphogenetic processes. Endothelial chemokines regulate immune cell approach and
transmigration across the blood and lymphatic endothelium. The evidence for mechanisms
regulating the extracellular chemokine cues are emerging (1–3). However, the sparsity of
endogenous gradients that can be detected at tissue level has hampered research on gradient
formation. CCL21 is the only chemokine, which has been directly shown to form functional
gradients in tissues at endogenous levels (2, 4), and thus presents a unique opportunity to study the
mechanistic basis of formation and maintenance of chemokine gradients.
CCL21 is secreted by lymphatic endothelial cells (LEC), shows the highest concentration at the
plasma- and basement membrane of the lymphatic capillary and forms a gradient decaying into the
surrounding interstitium (4–7). CCL21 is essential for the guidance of antigen-presenting CCR7org February 2021 | Volume 12 | Article 6300021
Vaahtomeri et al. Mechanisms of CCL21 Gradient Formationpositive dendritic cells (DC) from peripheral tissues to the
lymphatic capillaries and further into the parenchyma of
lymph nodes (2, 4, 5, 8, 9).
Most gradient forming proteins exist in a soluble and a glycan
anchored pool. The binding to proteoglycans, especially heparan
sulfates (HS), has been shown to shape fibroblast growth factor
gradients by limited diffusion (10, 11). Accordingly, genetic
deletion of the essential enzymes of HS synthesis resulted in
defective morphogen gradient formation: deletion of Ext2 and
Extl3, and thus absence of HS chain polymerization, lead to
enhanced FGF diffusion in zebrafish (12), whereas hypomorphic
allele of Ext1 resulted in elevated range of HS binding Indian
hedgehog in mouse embryos (13).
CCL21 interacts in vitro with glycans like HSs, chondroitin
sulfate B and E and also collagen IV via its positively charged
carboxy-terminus (14, 15). Accordingly, intact lymphatic
endothelial HSs are necessary for CCL21 anchoring to the LEC
surface in cell culture and the mesenchymal HSs for anchoring to
the interstitium of dermal explants (4, 16, 17). Based on these
data we hypothesized that LEC produced HSs are causative for
CCL21 sequestration at the CCL21 source, i.e. at the lymphatic
capillary, in vivo and thus regulate the shape of the interstitial
CCL21 gradient by limiting the CCL21 diffusion into the
interstitium. If true, deletion of LEC derived HSs might lead to
flattening of the interstitial CCL21 gradient shape, longer decay
length and thus might impair DC migration to the lymphatic
capillaries. To test this hypothesis, we specifically abrogated only
lymphatic endothelial HS production by a genetic approach and
show, surprisingly, that lymphatic endothelial produced HSs are
not essential for the formation of a functional CCL21 gradient.MATERIALS AND METHODS
Mice
All the mice were on a C57BL/6J background. Wild type mice were
purchased from Charles River and mTmG mice from Jackson
laboratories. Ext1flox mice were kindly provided by Yu Yamaguchi
and Holger Gerhardt (18), Prox1CreERT2 mice by Taija Mäkinen
(19) and Ccr7−/− mice by Reinhold Förster (20). Male and female
mice were bred and maintained according to the local rules
(Institutional Review Board approval BMWF-66.018/0005-II/3b/
2012). Prox1CreERT2;Ext1flox/flox, Ext1flox/flox, Prox1CreERT2;
Ext1flox/flox;mTmG and Ext1flox/flox;mTmG mice were topically
treated with acetone dissolved 4-OHT (10mg/ml) (Sigma-Aldrich)
once a day at P2-5. 4-OHT treated Prox1CreERT2;Ext1flox/flox and
Prox1CreERT2;Ext1flox/flox;mTmGmice are referred to as “Ext1DLEC”
whereas 4-OHT treated Ext1flox/flox and Ext1flox/flox;mTmG are
referred to as “control”. Ears were collected for further analyses or
treated with FITC at the age of 4 to 6 weeks. In each experiment
control and Ext1DLEC mice were littermates.
Sorting and Genotyping of Prox1CreERT2;
Ext1flox/flox;mTmG Ear Dermal Cells
Ears of the 4-OHT treated Prox1CreERT2;Ext1flox/flox;mTmG
mice were collected at 4 weeks age. Ears were split into ventralFrontiers in Immunology | www.frontiersin.org 2and dorsal halves, fat layer was removed, ears were minced and
treated with 1 mg/ml Collagenase A (Sigma-Aldrich) in DMEM
supplemented with 1.3 mM CaCl2 at +37°C for 1 h. The
collagenase A treatment was quenched with 10 mM EDTA at
room temperature for 10 min, tissue lysates were stripped
through 70 µm cell strainer, cells were collected by
centrifugation and subsequently resuspended to FACS buffer
(5mM EDTA in PBS). FACS Aria (Becton Dickinson) was used
to sort the cells to EGFP+ and tdTomato+ populations. Sorted
cells were collected by centrifugation and cell pellets were directly
lysed with genotyping sample buffer and used for genotyping of
Ext1flox allele, Ext1 deleted allele and Oaz1 (loading control).
Dendritic Cell Preparation
Mature dendritic cells (DCs) were generated by extracting bone
marrow from femur and tibia of 8–12 weeks old wild type orCcr7−/−
mice followed by culture in R10 medium (RPMI1640 containing
penicillin-streptomycin, glutamine, 10% fetal calf serum; all from
Gibco) supplemented with GM-CSF hybridoma supernatant. Day 8
DCs were activated with LPS (200 ng/ml, Sigma-Aldrich) for 20 h.
Activated DCs were labeled with 6.7 µM 5-(and-6-)
carboxytetramethyl rhodamine, succimidyl ester (TAMRA,
Molecular Probes, Life Technologies) in PBS at room temperature
for 15 min. The staining reaction was quenched by the addition of
R10, cells were collected by centrifugation and resuspended to the
R10 + GM-CSF hybridoma supernatant.
Ear Sheet Preparation, Interstitial
Dendritic Cell Migration Assay and
Heparinase II Treatment
Ear sheets were prepared as reported earlier (4). In short, ears
were split and the ventral ear sheets were either fixed with 4%
PFA for 25 min (Figures 1B, D), placed on PBS for antibody
staining of the native ear (Figures 2A, B) or mounted for
interstitial DC migration assay (Figure 2E) as follows: ventral
ear sheet was placed in between of a 0.5 ml PCR tube lid and the
cut top part of the tube, the latter forming a chamber filled with
R10. LPS activated TAMRA labeled wild type or Ccr7−/− DCs
were loaded on the exposed dermis of control or Ext1DLEC ears
and allowed to migrate for 60 min in a cell culture incubator with
5.0% CO2 and fixed with 4% PFA at room temperature
for 25 min.
As a negative control for heparan sulfate staining (Figure
1D), ventral ear sheets were treated with 150 µl of heparinase 2 (3
SU) in PBS supplemented with 0.1% BSA at +37°C for 2 h.
Following control or heparinase 2 treatment, ventral ear sheets
were washed three times with PBS and fixed with 4% PFA for
25 min at room temperature.
Ear Sheet Staining
For extracellular CCL21 staining (Figures 2A, B), native ventral
ear sheets were blocked with 1% BSA in PBS for 45 min. Control
Ext1flox/flox;mTmG ears were incubated with a-LYVE1 and
biotinylateda-CCL21 for 1 h 30 min, washed three times,
followed by staining with a-rat Alexa 488 and streptavidin-
Alexa 647 for 1 h and washed three times for a total of 30 minFebruary 2021 | Volume 12 | Article 630002
Vaahtomeri et al. Mechanisms of CCL21 Gradient Formationwith PBS. The Ext1DLEC ears (Prox1CreERT2;Ext1flox/flox;mTmG)
were treated similarly, but the a-LYVE1 and a-rat Alexa 488
were omitted due to lymphatic endothelial EGFP expression (see
Figure 1B, for the specificity of EGFP expression). Ears were
imaged immediately.
For staining of LYVE1 and heparan sulfates (Figure 1D) the
fixed ears were blocked with 1% BSA in PBS for 1 h. Before
antibody staining, 1:50 diluted a-HS (mouse monoclonal IgM, k)
(10E4; US Biological) was pre-incubated with biotinylated
a-mouse antibody (vector labs) for 60 min at room
temperature in blocking buffer. The a-HS (10E4)-anti-mouse
antibody complex with or without a-LYVE1 (1:200 dilution;
R&D MAB2125) were incubated on blocked ears in blocking
buffer for 2 h. The ears were washed three times, incubated with
a-rat Alexa-488 secondary antibody and streptavidin-647 and
washed three times. All the images were captured with uprightFrontiers in Immunology | www.frontiersin.org 3Zeiss LSM700 confocal microscopy by using Zen black
imaging software.
Image Analyses
The margins of LYVE1 positive lymphatic vessels (LV) were
manually drawn to allow the segmentation of overview images
(Figure 2B). For the quantification of LV bound CCL21 (Figure
2C), the average CCL21 intensity overlapping with the LV mask
in control and Ext1DLEC mice was quantified. For CCL21
gradients (Figure 2D), CCL21 intensity outside of the mask
was measured as a function of distance from the nearest LV
mask margin.
For the quantification of interstitial DC migration (Figure
2E), DCs were identified by thresholding TAMRA channel
images. The distance of each identified DC was measured to
the nearest LV margin. As a control of random DC distribution,A B
D
C
FIGURE 1 | Prox1CreERT2 driven Ext1 deletion results in a drop of lymphatic endothelial heparan sulfates below detection limit in vivo. (A) Schematic illustration
depicts the used strategy for deletion of Ext1 in lymphatic endothelium. Prox1 promoter mediated expression of CreERT2 and subsequent tamoxifen dependent
CRE activation leads to the deletion of the first exon of Ext1 (and thus lack of EXT1 protein production) and concomitant switch- on of the Egfp in LECs. pA stands
for polyadenylation signal. (B) A wholemount image of mouse ear dermis (EGFP, green; LYVE1 staining, white) of tamoxifen-treated Prox1CreERT2;Ext1flox/flox;mTmG
mouse (Ext1DLEC). Scale bar 500 µm. The tiled image was captured with a 10x objective. (C) Genotyping of sorted EGFP or tdTomato positive primary cells of two
pooled Ext1DLEC mouse ears. Image shows PCR product of the Ext1flox allele exclusively in non-recombined red cells and the PCR product of the deleted Ext1 allele
exclusively in the recombined green cells. Oaz1 presents a loading control. (D) LYVE1 (green) and HS staining (white) of control dermis and HS staining (white) of
EGFP expressing Ext1DLEC dermis. Heparinase II treatment of control dermis is used as a control for a-HS specificity. Yellow arrows indicate lymphatic and red
arrows blood endothelial decoration by HSs. Green arrows indicate the drop of lymphatic endothelial HSs below the detection limit upon Ext1 deletion. Blue arrow
indicates heparinase II insensitive bright staining on isolate cells. Scale bar 50 µm. Images were captured with 20x objective.February 2021 | Volume 12 | Article 630002





FIGURE 2 | Lymphatic endothelial heparan sulfates are not required for chemokine CCL21 gradient formation. (A) High magnification and (B) overview images of
non-permeabilized CCL21 (white) and LYVE1 (green) stained control dermis or CCL21 (white) stained and EGFP (green) expressing Ext1DLEC dermis. Yellow arrow
indicates extracellular CCL21 deposits, which possibly represent the sites of DC triggered CCL21 secretion (5). Scale bars 20 and 200 µm, respectively. (C) Bar
graph shows mean (+/− SD, p-value = 0.055) CCL21 intensity at the lymphatic vessel i.e. CCL21 staining overlapping with LYVE1 staining or EGFP signal (green).
N= 8 independent control and Ext1DLEC mouse ears. (D) Line graph shows a quantification of the mean (+/− SD) interstitial CCL21 intensity in control (black line) and
Ext1DLEC (red line) mouse ear dermis as a function of distance from the nearest lymphatic vessel margin. N= 4 independent control and five Ext1DLEC mouse ears.
(E) Images show LYVE1 stained (green) lymphatic vessels and TAMRA labeled DCs (white) after 60’ of migration. The associated bar graph shows mean (+/− SD)
migration efficiency of DCs toward lymphatic capillaries in control and Ext1DLEC ears (p-value = 0.93). The Ccr7−/− DCs are unable to sense CCL21 and thus show
random distribution (p-value<0.001). N=14 independent ears for “wt on control” 12 for “wt on Ext1DLEC” and 6 for “Ccr7−/− on control”. Scale bar 200 µm.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 12 | Article 6300024
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distances were quantified. The efficiency of migration was
evaluated by dividing the real mean distance of DCs to the
LVs by the mean distance of the control measurement. Finally,
results were presented as normalized to the average of wild type
DCs on control ears.FITC Painting and Analyses of Lymph
Node Cellularity
Ten percent FITC stock solution was dissolved 1:5 in a 1:1 mix of
Acetone and DBP (Dibutyl-Phtalate). The 5 weeks old 4-OHT
treated control (Ext1flox/flox) or Prox1CreERT2;Ext1flox/flox
(Ext1DLEC) mice were anesthetized with isoflurane and both the
ventral and dorsal sides of the ears were painted with 25 µl of the
FITC suspension. Seventy-two hours later, cervical lymph nodes
were harvested and placed on ice in RPMI1640 supplemented
with 10% FCS and 5 mM EDTA, smashed, centrifuged and
resuspended in RPMI1640 supplemented with 10% FCS and 5
mM EDTA. The 3*106 cells/96well were blocked with a-CD16/
32 and stained with a-CD11b BV421, a-MHC II (I-A/I-E) BV
510, a-CD103 PE, a-CD8 PerCP-Cy5.5, and a-CD11c PE-Cy7
(BD Biosciences). Subsequent to 45-minute incubation cells were
washed once, resuspended in PBS and immediately fixed with 2%
PFA at room temperature for 20 min. Fixed cells were washed
once, slowly resuspended in PBS 0.25% saponin for 10 min and
then stained with a-langerin Alexa-647 (Dendritics) for 30 min.
Cells were washed twice, resuspended in PBS and analyzed with
FACS Aria.
The stepwise gating strategy was: 1. FSC-A vs. SSC-A gating.
2. FSC-A vs. FSC-W single cells gating. 3. MHCII vs. CD11c
gating was used for the identification of a. lymph node resident
(MHCIIint CD11chigh) and b. migratory DCs (MHCIIhigh
CD11cint). 4. Migratory DCs were further defined to 4
populations based on CD103 vs. langerin gating. 5. Upon FITC
painting there were no FITC positive cells in the resident DCs
population whereas migratory FITC positive cells were
abundant. Further, there were no FITC positive cells in the
samples derived from non-painted mice.
The proportion of FITC+ migratory DCs and FITC+
Langerhans cellslangerin+ CD103- to all migratory DCs in the
cervical lymph nodes and total lymph node cellularity were
quantified. The results of left and right cervical lymph nodes
from a single mouse were pooled and used as a single data point.
The results are shown in Figure 3.
Statistics
Normality of the data was tested with Shapiro-Wilk and
Kolmogorov-Smirnov tests and the statistical significance was
tested with the Student’s t-test with two-tailed distribution and
Welch’s correction (Prism software, GraphPad software).RESULTS
To study the contribution of lymphatic endothelial heparan
sulfates to CCL21 gradient formation, we specifically preventedFrontiers in Immunology | www.frontiersin.org 5HS production in LECs by deletion of Ext1, a rate-limiting gene
in the HS synthesis pathway. Lack of Ext1 expression leads to a
loss of HSs in vivo and in vitro (18, 21, 22). To induce the
deletion of Ext1 in the mouse ear dermis lymphatic endothelium,
we generated Prox1CreERT2;Ext1flox/flox;mTmG mice, in which
tamoxifen-induced recombination is reported by a switch on of
EGFP and switch off of tdTomato (Figures 1A–C). Indeed, upon
tamoxifen treatment, EGFP was observed exclusively in the
lymphatic endothelium (Figure 1B), indicating that
Prox1CreERT2 has been expressed specifically, and at sufficient
levels, in all the LECs of lymphatic capillaries. Genotyping of the
extracted mouse ear dermal LECs, marked by EGFP, detected
only the deleted Ext1 allele whereas the non-recombined cell
types contained only the non-deleted Ext1flox allele (Figure 1C).
Wholemount immunofluorescence staining of mouse ears
demonstrated that HSs specifically decorate lymphatic and
(more intensely) blood endothelium of control mice. In line
with the lymphatic endothelial-specific Ext1 deletion, HSs were
lost below the detection limit specifically in LECs, but not in
blood endothelium or interstitium of tamoxifen-treated
Prox1CreERT2;Ext1flox/flox;mTmG mice (Figures 1C, D). These
results suggest that LECs are the major source of perilymphatic




FIGURE 3 | Efficient DC homing to lymph nodes in Ext1DLEC mice upon FITC
painting. (A, B) Bar graphs show mean (+/− SD) percentage of FITC+, CD11cint,
MHCIIhigh DCs of (A) total lymph node cellularity (p-value = 0.53) (B) and
migratory DCs (CD11cint, MHCIIhigh) (p-value = 0.087) in lymph nodes of control
or Ext1DLEC mice. (C, D) Shows mean (+/- SD) percentage of FITC+, CD11cint,
MHCIIhigh, langerin+, CD103- Langerhans cells of (C) total lymph node cellularity
(p-value = 0.68) and (D) migratory DCs (CD11cint, MHCIIhigh) (p-value=0.65) in
lymph nodes of control or Ext1DLEC mice. (E) Shows mean (+/- SD) absolute
number of CD11cint, MHCIIhigh migratory DCs (p-value = 0.90) in lymph node of
control or Ext1DLEC mice. N= 5 independent samples/genotype.February 2021 | Volume 12 | Article 630002
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produced HSs on CCL21 presentation by LECs in vivo, we
wholemount stained the exposed mouse ear dermis.
Extracellular CCL21 levels at the lymphatic capillary of
Ext1DLEC mice were only modestly decreased in comparison to
control mice (Figures 2A–C). Thus, in contrast to earlier in vitro
results (14, 16, 17), lymphatic endothelium produced HSs are
largely dispensable for CCL21 binding to lymphatic capillaries
in vivo.
Analyses of the interstitial CCL21 intensity showed similar
CCL21 gradient shape in control and Ext1DLECmice (Figures 2B,
D). Next, we functionally validated these data by ex vivo DC
migration assays. Activated DCs were loaded onto exposed
dermis of split ears, which triggers directed migration of DCs
toward the lymphatic capillaries (4). Wild type DCs were as
effective in approaching the lymphatic capillaries in control and
Ext1DLEC ears whereas Ccr7 deficient DCs, which are unable to
sense CCL21, were randomly distributed in control ears
(Figure 2E).
To complement our ex vivo findings, we compared DC
homing to lymph nodes of control and Ext1DLEC mice 72 h
after FITC-painting. The proportion of FITC+ migratory DCs of
total lymph node cellularity and total lymph node migratory DCs
was comparable in control and Ext1DLEC mice (Figures 3A, B).
Importantly, also the proportion of the FITC+ epidermal
subpopulation of DCs, the Langerhans cells, was similar in
control and Ext1DLEC mice when compared to the lymph node
total cellularity or lymph node migratory DCs (Figures 3C, D).
Since the peak of the Langerhans cell homing to the draining
lymph nodes is at day 4 after immunization (23), this result
shows that the first Langerhans cells arrive in lymph nodes
efficiently in time also in Ext1DLEC mice, further supporting the
existence of normal CCL21 guidance cues in the absence of
lymphatic endothelial HSs. Also, the absolute number of lymph
node total migratory DCs (FITC+ and FITC−) was unaltered
upon deletion of Ext1 (Figure 3E).DISCUSSION
Our studies show that, in our model system, LEC produced HSs
are dispensable for the formation of the mesenchymal CCL21
gradient (Figures 2B, D). We deleted Ext1 before the
establishment of a mature dermal lymphatic vessel network,
which resulted in a drop of HSs, both at the LEC surface and
basement membrane, below the detection limit (Figure 1D).
Earlier, it has been shown that binding of CCL21 on the LEC
surface in vitro is dramatically reduced upon Ext1 deletion (17).
We show that in vivo Ext1 deletion results only in a modest
reduction of the lymphatic capillary associated CCL21 (Figures
2A–C). Thus it is conceivable that also in vivoHSs are needed for
CCL21 binding to the LEC surface, but that the peri-lymphatic
capillary matrix, in an HS-independent manner, is the major site
of CCL21 anchoring. In support of CCL21 binding on the
extracellular matrix at the lymphatic capillary, an earlier study
showed that lymphatic capillary associated CCL21 deposits areFrontiers in Immunology | www.frontiersin.org 6removed by collagenase treatment (24). The candidate molecules
mediating CCL21 anchoring to the cell-matrix in the absence of
HS include basement membrane component collagen IV and
proteins bearing chondroitin sulfate B and E moieties (14, 15).
Interestingly, gradient formation of Indian hedgehog is regulated
by both HSs and chondroitin sulfates in mice in vivo (13, 25).
We show that in our model system LEC-produced HSs are
dispensable for DC migration toward lymphatic capillaries
(Figure 2E). In contrast, in an earlier study by Bao et al., TEK-
Cre-deleter driven Ext1 deletion in blood and lymphatic
endothelium and leukocytes was shown to cause attenuated
homing of intradermally injected wild type bone marrow-
derived DCs to lymph nodes (17). It is conceivable that blood
endothelium or leukocyte HSs are needed for dispersion or
sequestration of systemic signals, which affect DC activation
and/or migration to lymphatic vessels. In studies by Yin et al.,
lymphatic endothelial HS production was prevented by
deletion of Ndst1, an enzyme downstream of EXT1 in the HS
synthesis pathway, whose deletion results in altered HS fine
structure by preventing N-sulfation. Deletion of lymphatic
endothelial Ndst1 resulted in a decreased xenograft tumor cell
metastases to lymph nodes and oxazolone induced lymph
node homing of DCs possibly via defective CCL21
oligomerization and/or promotion of CCR7-CCL21 interaction
rather than anchoring to the matrix (16, 26). It is noteworthy
that DC CCL21-CCR7 signaling is dependent on the
polysialylation of the receptor (27). Thus, it is conceivable that
non-sulfated HSs glycan backbones, created upon Ndst1
dele t ion , could inter fere wi th s ia l i c ac id- induced
conformational changes in CCL21. Our studies also differ in
terms of the onset of the prevention of the HS synthesis. Whereas
we deleted Ext1 at early postnatal development to prevent LEC
produced HS deposition to the lymphatic capillary basement
membrane, Yin et al. deleted Ndst1 only after maturation of the
dermal lymphatic capillary network and deposition of the
basement membrane (26, 28).
Recently, Arokiasamy et al. showed a dramatic reduction in
HS coverage of lymphatic capillaries upon inflammatory
stimulus (29). Interestingly, a decrease in the HS coverage of
lymphatic capillaries was essential for efficient tissue fluid
drainage, but, importantly, not CCL21 dependent migration
and entrance of neutrophils to lymphatic capillaries (29, 30).
Together with our study, these results show that CCL21
dependent leukocyte migration cues are not affected by the
changes in lymphatic endothelial HSs. However, it is
conceivable that the HS may regulate DC trafficking in a
CCL21 independent manner via mechanisms that were not
captured by our model system, for example via tissue
fluid drainage.
In conclusion, we show that prevention of the HS production
at the source of the CCL21 production does not prevent handing
over of the CCL21 chemokine to the mesenchymal HSs (Figure
4), which are necessary for the interstitial CCL21 anchoring and
gradient (4). To our knowledge, earlier studies showing a
necessary role for HSs in growth factor/morphogen gradient
formation have deleted HS production in all the cell-types or aFebruary 2021 | Volume 12 | Article 630002
Vaahtomeri et al. Mechanisms of CCL21 Gradient Formationclone of all the cells. Here, we have been able to delete HSs only at
the source of CCL21 production, leaving HSs at the site of the
gradient (interstitium) intact (Figure 4). These results highlight
the significance of the microenvironment on CCL21 binding and
show that not the molecular identity but rather the presence of
any diffusion limiting interactions at the lymphatic capillary is
sufficient for regulation of CCL21 gradient shape and
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